Yeah, I'm sure patients failing 4-5 treatments didn't have a major impact on the mortality and ORR, Precision's ORR is 80% and IMU's can be 85% if those 2 SD become PR or CR, the percentage of CR are around the same for both. Also, how many multiple treatments did the patients in the clinical trial done by Precision failed? The dose get escalate to 500 x 10^6 CAR T cells (flat dose) and 1000 x 10^6 CAR T cells (flat dose) compared to 540 x 10^6 CAR T cells (flat dose) done by Precision.
Mentioned what to the shareholders??? IMU only saw the problem with Cohort A so use a combination of IL-2 for Cohort B to address the slow efficacy seen which has probably delay the clinical trial by 6 months. And again, the purpose of the Azer-Cel acquisition is for CD19 to combine with CF333 to eradicate "target-less" tumour and open the market to 90% of solid cancer market.
IMU Price at posting:
4.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)